Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Events

Events

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Events
  • News

NVIDIA 2023 Annual Meeting Of Stockholders Online Set For Thursday, June 22, 2 p.m. ET

By Happy Mohamed
Yesterday, 5:05 PM
NVIDIA today announced it will hold its 2023 Annual Meeting of Stockholders online on Thursday, June 22, at 11 a.m. PT. The meeting will take place virtually

NVDA

Read More
1 minute read
  • Biotech
  • Events
  • General
  • News

Sagimet Biosciences To Present Interim Data From Phase 2b Trial Of Denifanstat In NASH At EASL Congress 2023

By Benzinga Newsdesk
June 7, 9:03 AM
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the FASCINATE-2 Phase

SGMT

Read More
3 minute read
  • Cryptocurrency
  • Events
  • Markets
  • News

Polkadot Decoded 2023 Brings Web3 Community to Denmark with Speakers from Vodafone, Deloitte, and More

By Jose Rodrigo Safdiye
June 6, 1:19 PM
  Fourth edition of the flagship event to bring together Web3's biggest multichain ecosystem in the biggest annual gathering of the Polkadot community

$DOT

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Events
  • Large Cap
  • News
  • Price Target
  • Tech

Apple Stock Hits Record High During WWDC, Tumbles After Vision Pro AR Headset Price Tag Unveiled

By Piero Cingari
June 5, 3:24 PM
Apple's highly anticipated Worldwide Developers Conference (WWDC23) event sent waves of enthusiasm throughout the tech community as the tech titan unveiled a wave of innovative products and features with

AAPL

Read More
2 minute read
  • Events
  • General
  • News
  • Politics
  • Top Stories

Decades Long ‘Gay Days’ Festivities Return To Florida Despite DeSantis Vs. Disney Drama

By Melanie Schaffer
June 5, 10:47 AM
Walt Disney Co’s (NYSE: DIS) Gay Days kicked off PRIDE month, defying Florida governor Ron DeSantis who has been in a year-long feud with the entertainment giant

DIS

Read More
1 minute read
  • Events
  • News

Janssen Announced First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma At ASCO

By Charles Gross
June 3, 2:40 PM
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific

JNJ

Read More
6 minute read
  • Biotech
  • Events
  • General
  • News

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence With Imetelstat In IMerge Phase 3 Lower Risk MDS Patients

By Happy Mohamed
June 2, 3:31 PM
Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders Statistically

GERN

Read More
3 minute read
  • Biotech
  • Events
  • General
  • News

Reported Earlier, Autolus Therapeutics Presents Results From Pivotal Phase 2 FELIX Study In Adult r/r B-ALL At ASCO

By Happy Mohamed
June 2, 9:00 AM
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis   Potential best in class tolerability,

AUTL

Read More
2 minute read
  • Biotech
  • Events
  • General
  • News

Neurocrine Biosciences Presents INGREZZA Capsules Data On Tardive Dyskinesia Improvement Regardless Of Baseline Antipsychotic Use At 2023 Psych Congress Elevate

By Benzinga Newsdesk
June 2, 8:32 AM
 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA® (valbenazine) capsules that demonstrated substantial and sustained

NBIX

Read More
1 minute read
  • Events
  • News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

By Charles Gross
June 2, 6:47 AM
BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX

Posts navigation

1 2 … 68 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service